Last Updated： Aggregation Period:Feb 11, 2026～Mar 10, 2026
This ranking is based on the number of page views on our site.
Last Updated： Aggregation Period:Feb 11, 2026～Mar 10, 2026
This ranking is based on the number of page views on our site.
Last Updated： Aggregation Period:Feb 11, 2026～Mar 10, 2026
This ranking is based on the number of page views on our site.
1～30 item / All 611 items
Comprehensive workflow solution for Agilent's oligonucleotides.
Agilent supports a comprehensive workflow that incorporates optimized instruments, software, columns, and consumables for oligonucleotide analysis. Additionally, Agilent also supports GMP manufacturing of commercial quantities of oligonucleotides in later stages.
Five manufacturing buildings, a quality control building, an office building, and a wastewater treatment facility are all included! It has a manufacturing license for pharmaceuticals.
Tateyama Kasei Co., Ltd.'s Kyushu factory is located in Tagawa City, which is situated in the central part of Fukuoka Prefecture. It began operations in 1972 and is equipped with five manufacturing buildings, a quality control building, an office building, and wastewater treatment facilities. Notable equipment includes an indirect cooling type ultra-low temperature reaction device and a filtration dryer. The factory holds a manufacturing license for pharmaceuticals and has two lines of 6000L active pharmaceutical ingredient purification equipment, making it suitable for the production of relatively large quantities of stable active pharmaceutical ingredients. [Features] - Possesses an indirect cooling type ultra-low temperature reaction device and a filtration dryer - Holds a manufacturing license for pharmaceuticals - Well-suited for the production of relatively large quantities of stable active pharmaceutical ingredients *For more details, please refer to the PDF document or feel free to contact us.
BRAFV600E mutation cancer treatment agent
The BRAFV600E mutation is observed in multiple cancer types and is associated with a poor prognosis compared to other molecular subtypes. In the treatment of BRAF-mutant colorectal cancer patients, targeted therapies have been developed and clinically introduced in 2020, including combination therapies of BRAF inhibitors with anti-EGFR antibody drugs, as well as a three-drug combination therapy of BRAF inhibitors, MEK inhibitors, and anti-EGFR antibody drugs. However, BRAF-mutant colorectal cancer still has a poor prognosis, and further effective treatment strategies are needed. Therefore, this invention proposes that retinoid receptor (particularly RARα or RXRα) agonists can enhance treatment effects or overcome acquired resistance in combination therapies of BRAF inhibitors with anti-EGFR antibody drugs or BRAF inhibitors, MEK inhibitors, and anti-EGFR antibody drugs, potentially serving as an effective treatment strategy for cancers with BRAFV600E, particularly colorectal cancer.
Components found in mammalian milk suppress the progression of kidney disorders, sarcopenia, and anemia.
Chronic kidney disease currently affects about 1 in 8 adults and is said to be a new national disease in Japan. The treatment aims to slow the progression of symptoms, particularly to prevent the progression to end-stage renal failure and the onset of cardiovascular diseases. CKD also has complications such as bone disorders, muscle atrophy (sarcopenia), and anemia, and there are no effective treatments available. This invention relates to the effects of a protein called lactoferrin (Lf) on the progression and complications of chronic kidney disease (CKD). It was found that the administration of Lf has both preventive effects before the onset of CKD and therapeutic effects after its onset in adenine-induced renal failure model mice (Reference 1). Specifically, the effects of Lf in suppressing sarcopenia (reduction of muscle cross-sectional area, decrease in the accumulation of uremic toxins in muscles), anemia, renal atrophy, tubular interstitial damage, decline in kidney function, and inflammation and fibrosis in the kidneys were confirmed.
Drug repositioning of Lubiprostone Exploratory P2 is over!
Toxin adsorbents such as SGLT2 inhibitors and cremedin have been used as pharmacotherapy for kidney disease. Lubiprostone, which is also used as a constipation drug, was shown to be effective as a treatment for chronic kidney disease (CKD). Lubiprostone was also found to suppress the decline in renal function. In an investigator-initiated clinical trial, the inventors conducted an exploratory study to investigate the efficacy and safety of 8 μg/day and 16 μg/day of lubiprostone in reducing renal function in patients with chronic kidney disease, using a placebo control. (The results can be disclosed under individual contracts.)
Over 1000 times affinity to bind with RNA virus (vs. DPQ)! Promising diagnostic and inhibitory drug!
Introduction Influenza prevails broadly every season. Current diagnostic drugs can not be performed until the virus increases quite a lot (ca. 12~24h after infection, symptoms may appear), and if not so, both sensitivity and accuracy of the test will be doubtful. To prevent on-going severe symptoms, new diagnostic tech for influenza at earlier stage becomes so demanded. This invention provides a conjugate of peptide nucleic acid sequence (PNA) and a small molecule, targeting the commonly identical RNA hairpin promoter region of eight kinds of influenza A virus. Effect & Application The conjugate (tFIT-DPQ probe) is composed of two parts: tFIT unit for recognition of virus RNA’s nucleotides and DPQ* unit for UAA internal loop binding. In tFIT unit, a fluorescent ligand is inserted so as to be capable to emit signals when intercalating to RNA duplex (Fig. 1). The conjugate shows an over 1000 times greater binding affinity than DPQ molecule only (Fig. 2). By simply mixing the virus RNA contained sample and the conjugate together, test result will be obtained within a short time (ca. 2~3 min) and 1nM virus RNA (ca. 1010 copies) can be detected. Moreover, the virus inhibition effect by the conjugate in micromolar range was confirmed (Fig. 3). tFIT-DPQ probe is expected to be applied as diagnostic and inhibitory drugs, as well as a screening tool for influenza drug candidates.
New drug discovery seeds for psychiatric disorders such as schizophrenia
Recent large-scale genomic and postmortem brain analyses have indicated that synaptic dysgenesis may be involved in the pathogenesis of schizophrenia, but the detailed mechanisms remain unclear. Drugs mainly blocking dopamine D2 receptors have been used for the treatment of schizophrenia, but they are mainly used for symptomatic treatment and have insufficient effects on negative symptoms and cognitive dysfunction. Therefore, it is desirable to develop new drugs based on new molecular mechanisms. The inventors have discovered that the decreased function of the PPARA gene, which encodes the nuclear receptor PPARα, is involved in the pathogenesis of schizophrenia [1]. Since PPARα is a transcription factor that can be activated by its ligand, they considered the possibility that activation of PPARA might lead to the improvement of schizophrenia, and found that fenofibrate, a PPARa agonist, is actually effective in improving synaptic function [2]. In this study, they found that pemafibrate, a PPARa agonist, helps to improve cognitive function at the same time as restoring spine density in mice. The invention could lead to the discovery of novel mechanisms for schizophrenia. Furthermore, since decreased spine density and cognitive decline are similar symptoms in other psychiatric disorders such as Alzheimer's, it could also be a therapeutic agent for these disorders.
Everything from order receipt to manufacturing is done within Japan! We significantly reduce the time and effort our customers spend on complicated tasks.
We would like to introduce the artificial gene synthesis from Fasmac Co., Ltd., which we handle. The synthesized sequences will be delivered in a plasmid form after being introduced into a vector as double-stranded DNA. In addition to the standard pUC series vectors from the company, we can also accommodate cloning into specified vectors provided by you. All processes from order to manufacturing are conducted domestically in Japan, and our specialized staff will respond quickly and meticulously. This significantly reduces the time and effort our customers spend on complicated tasks such as PCR, cloning, and sequencing analysis. 【Service Items】 ■ Express Course - Up to 1,500 bp / 1,501 to 3,000 bp / 3,001 to 4,000 bp ■ Standard Course - Up to 1,500 bp / 1,501 to 3,000 bp / 3,001 to 4,000 bp - 4,001 to 6,000 bp / 6,001 to 10,000 bp *For more details, please refer to the PDF document or feel free to contact us.
PCR kit series capable of detecting new coronavirus genetic material and screening for S-protein mutations.
KogeneBiotech, established in 2000, is the top manufacturer of gene detection kits in South Korea and currently manufactures and sells over 500 items of real-time PCR and conventional PCR kits. In February 2020, KogeneBiotech received the first approval in South Korea for the "PowerChek 2019-nCoV Real-time PCR Kit" as an in vitro diagnostic medical device (IVD), and since then, it has developed and sold various real-time PCR reagents related to the novel coronavirus (SARS-CoV-2). Each kit includes all the necessary reagents for measurement, such as enzymes and positive controls, enabling rapid and accurate detection of the novel coronavirus genes. ★ This kit series is for research and testing purposes only. It has not received approval or certification as an in vitro diagnostic medical device.
We have various reagents available for preparing buffer solutions such as Tris and HEPES.
In the field of biochemistry research and experiments, buffers play an important role. Currently, we offer a variety of reagents for buffer preparation, including widely used Tris and HEPES, which has minimal impact on living organisms. ●Example of a product 【Special Grade 2-Amino-2-Hydroxymethyl-1,3-Propanediol (Tris)】 In the field of biochemistry, "2-Amino-2-Hydroxymethyl-1,3-Propanediol (abbreviated: Tris)" is utilized as a buffer. We have prepared a product of "special" grade that includes "absorbance (260 nm, 280 nm)" and "appearance" as guaranteed items, in addition to the "superior" grade specifications. This product emphasizes a balance between quality and cost required for research and development in biochemistry, enhancing cost performance. 【Features】 ■ Guarantees "absorbance (260 nm, 280 nm)" and "appearance" in addition to superior grade specifications. ■ High cost performance with a focus on the balance between quality and cost. ■ Capable of scaling up from lab scale. * For specific supply quantities, please consult us for details.
By simply adding this product to a cell-free translation system, you can efficiently synthesize proteins with non-natural amino acids in a short time.
○Quantitative: Non-natural amino acids can be introduced only at the desired position. ○Rapid and simple: Pinpoint labeled proteins can be obtained purified in about 2 hours. ○Variety: Non-natural amino acids labeled with fluorescence, biotin, etc., can be introduced.
We support consistent quality control from raw materials to active pharmaceutical ingredients, including method development and stability testing!
Otsuka Chemical Co., Ltd. offers pharmaceutical CDMO services. Utilizing organic synthesis technology cultivated over many years in pharmaceutical manufacturing, we provide a consistent service from special raw materials to intermediates and mid-sized active pharmaceutical ingredients. With over 60 years of experience in halogenation technology and our unique catalyst development technology, we respond to diverse needs. Please feel free to contact us when you need our services. 【Features】 ■ High pharmacological activity (OEB Category 4) with solid-phase synthesis / flow synthesis capabilities Newly established GMP-compliant multi-purpose plant ■ Consistent service from special raw materials to intermediates and mid-sized active pharmaceutical ingredients ■ Responding to diverse needs through halogenation technology and unique catalyst development technology *For more details, please refer to the PDF document or feel free to contact us.
Are you particular about the "freezing method" of pharmaceutical raw materials? It is possible to freeze and thaw raw materials more safely and securely while maintaining quality!
Of the biopharmaceutical active ingredients, 59.4% are transported in a frozen state. Therefore, the development of controllable and efficient freezing and thawing technologies is increasingly in demand. For example, in the development of COVID-19 vaccines, there has been a growing emphasis on storage and transportation methods, highlighting the necessity for these solutions. Recently, the combination of Allegro BioContainers and RoSS Technology has resulted in the development of an excellent active ingredient management solution through synergistic effects. It allows for the control of frozen active ingredients between the purification process and the formulation and filling processes, enabling stable and safe storage and transportation. Additionally, it prevents losses of active ingredients due to the breakage of frozen single-use packs, bringing the risk of loss close to 0%.
We will organize a total healthy happiness and comfortable environment.
Towa Pharmaceutical Co., Ltd. is a company that primarily manufactures patches, cooling sheets, and topical liquid agents. We prioritize quality assurance from the delivery of raw materials to manufacturing and shipping, and we have over 50 years of experience in the development and production of topical agents since our founding. 【Our Original Brands】 ■ Anti-itch and anti-inflammatory medication "Cocora EX" ■ Pain relief and anti-inflammatory agent "Koriafuta Series" ■ Cooling material for soft tissue therapy "Towa Sheet" *For more details, please download the PDF or feel free to contact us.
Introducing pH measurement reagents! The pH measurement range is from 6.0 to 7.6.
The "BTB Indicator (Bromothymol Blue Solution)" is an indicator for pH measurement. By adding this product at a ratio of 0.5 mL to 10 mL of the sample water in a transparent container (or colorimetric cell for measuring devices), pH can be measured within the range of 6.0 to 7.6. It is recommended to use a pH meter to compare the color of the colorimetric plate with the color of the sample water after adding the indicator for measuring the pH value. 【Features】 ■ Add this product at a ratio of 0.5 mL to 10 mL of the sample water ■ It is recommended to use a pH meter to compare the color of the colorimetric plate with the color of the sample water after adding the indicator for measuring the pH value *For more details, please refer to the PDF document or feel free to contact us.
Introduction of compounds expected to be developed as new NASH treatments.
At Renac Therapeutics, we handle "Pharmaceutical Pipeline NASH Therapeutics (Nucleic Acid Medicines)." Using our proprietary technology, Hetero Double-Stranded Nucleic Acid (HDO) technology, we have discovered compounds that inhibit the expression of the NASH-related gene IHH. These compounds are expected to improve the NAFLD activity score in NASH animal models by inhibiting IHH expression, paving the way for the development of a novel NASH therapeutic. [Features] - Effectively inhibits the expression of the NASH-related gene IHH. - Also suppresses the expression of fibrosis marker genes such as COL1A1, CTGF, and TIMP1, suggesting potential as a fibrosis treatment. *For more details, please refer to the PDF document or feel free to contact us.
Detailed data on reaction conditions and crystallization conditions can be obtained, leading to quality assurance through the manufacturing process!
We would like to introduce our "Process Chemistry Development Using PAT." The quality of active pharmaceutical ingredients (APIs) is believed to depend on the depth of understanding of the manufacturing process. By using PAT, detailed data on reaction conditions and crystallization conditions can be obtained, leading to assurance of quality through the manufacturing process. If formulation does not proceed well, such as unstable dissolution test results, the cause may lie in the crystal form of the API. PAT allows for real-time monitoring of the crystallization process. 【Features】 ■ Setting of reaction conditions ■ Setting of crystallization conditions ■ Setting of manufacturing processes *For more details, please refer to the related links or feel free to contact us.
Suitable for measuring chemical oxygen demand (COD) of various water qualities!
This test reagent is suitable for measuring the chemical oxygen demand (COD) of various water qualities, including surface water, groundwater, municipal wastewater, and industrial effluent. Please note that if the concentration of chloride ions in the sample is 1500 mg/L or higher, it may affect the measurement results, so please dilute the sample liquid with pure water before use. 【Features】 ■ Measurement Principle - Spectrophotometric method, dichromate method (CODcr) ■ Chloride Ion Interference - ≤2000 mg/L ■ Processing Time - 20 min @ 165℃ *For more details, please refer to the PDF document or feel free to contact us.
To further enhance gloss, color development, and strength! We propose suitable materials utilizing the technology of ceramic tile glazes.
"Glaze" is an essential product that enables the luster and diverse coloration of tiles, serving as a material to enhance strength. It is a type of glass that covers the surface of ceramics, such as pottery, essentially acting as a coating material for ceramics. It contains various components, which give it distinctive design and functional characteristics. At our company, we leverage this technology, developed over many years, to propose suitable products tailored to specific applications. [Examples of Applications] ■ Tiles with a glass-like luster ■ Tiles with metal crystals precipitated on the surface ■ Tiles finished with a matte surface that reflects light diffusely, etc. *For more details, please refer to the related links or feel free to contact us.
We will leverage our forward-thinking creativity and technological capabilities to contribute to the future of life sciences.
Sogo Yakuco started as an active pharmaceutical ingredient manufacturer producing substances such as Sulfisozine, Sulfadimethoxine, and Taurine. Leveraging the synthetic technologies acquired through active pharmaceutical ingredients, we engage in the development and manufacturing of functional cosmetic ingredients, recording materials, and electronic materials. With the keywords "safety," "technical capability," "speed," "quality," and "environment," we strive to meet the needs of the life sciences sector with a spirit of "challenge" and continuous corporate efforts. 【Business Activities】 ■ Manufacturing, sales, and import/export of pharmaceutical active ingredients, veterinary pharmaceuticals, and functional cosmetic ingredients ■ Manufacturing, sales, and import/export of fine chemical products such as specialty chemicals and chemical industrial products *For more details, please refer to the PDF materials or feel free to contact us.
![[Column] Management Strategies for Starting Materials in Active Pharmaceutical Ingredients](https://image.mono.ipros.com/public/product/image/3e5/2000710289/IPROS06292587954207697823.png?w=280&h=280)
The selection of starting materials significantly impacts the manufacturing cost of active pharmaceutical ingredients. We would like to introduce our management strategy for starting materials in active pharmaceutical ingredient production.
The selection of starting materials (hereinafter referred to as starting materials) for applications is proposed by pharmaceutical companies in accordance with the general principles of ICH guideline Q11, but it is often the case that they receive frequent inquiries from authorities before approval. At SpiraPharma, when selecting starting materials, organic chemists and analytical chemists collaborate to propose which compounds are suitable as starting materials based on the manufacturing process. Additionally, when establishing management strategies for starting materials, we can obtain data to support responses to authorities through investigations of the behavior of key related substances. For our customers who are challenging the creation of new pharmaceuticals, we will continue to leverage our cultivated technology and experience while furthering our expertise. *For more detailed information on the column, please refer to the related link. For further inquiries, please feel free to contact us.
[December 15 Event] A must-see for those involved in the synthesis of low molecular weight pharmaceuticals! Introduction to efforts in asymmetric synthesis reactions and more.
We are pleased to announce that our company will be hosting a webinar on "Pharmaceutical Active Ingredient Manufacturing Processes Utilizing Catalytic Asymmetric Synthesis" on December 15th (Thursday). In the synthesis of active pharmaceutical ingredients for low molecular weight drugs, when the target compound is a chiral compound with an asymmetric center, utilizing asymmetric synthesis that can synthesize the desired stereoisomer with high selectivity is extremely useful in the industry. At SpiraPharma, we have received requests from various customers to examine the asymmetric synthesis of target compounds, and we are advancing the application of asymmetric reactions centered on catalytic asymmetric hydrogenation to pharmaceutical processes. In this webinar, we will introduce our efforts in asymmetric synthesis reactions. We encourage anyone interested to participate. 【Event Overview】 ■ Date and Time: December 15th (Thursday) 11:00 AM - 11:30 AM ■ Participation: Free ■ Venue: Webinar via Teams *For more details, please refer to the related links or feel free to contact us.
A supercritical extraction of sandalwood essential oil that delivers exquisite healing, concentrated with the power of nature.
Storax (Styrax) essential oil is a 100% natural essential oil with a mysterious fragrance known since ancient times. This product is extracted from the trees of Liquidambar orientalis Mill., using carefully selected materials and the supercritical carbon dioxide (CO2) extraction method, which maximizes extraction without destroying the components. This extraction method offers higher purity compared to others, fully bringing out the essential oil's inherent effects. Storax essential oil features a deep, relaxing scent, making it ideal for stress relief and refreshing the mind and body. It is widely used in aromatherapy, massage oils, skincare products, and contributes to creating a pleasant atmosphere. We are confident in our quality, and it is highly regarded in overseas markets. Our company handles over 300 types of essential oils, and all products are available for OEM production. We can also provide packaging and blends tailored to customer needs, and our essential oils are suitable not only for cosmetics and aromatherapy but also for food and pharmaceutical applications.
Keywords: complex carbohydrates, glycan, organic synthesis, bioorganic chemistry, fluorescence, polymer science, bioactive substances, structure-activity relationship, next-generation antibodies.
The structure formed by sugars like glucose linked together in a chain is called a glycan, and a glycan made up of a few sugars is referred to as an oligosaccharide. The structure of these glycans determines blood types such as type A and type B! Additionally, glycans are involved in infections caused by viruses like influenza. Various glycans are actively functioning in our daily lives. Although there is no medical department, we conduct research and development in drug discovery related to detection, diagnosis, and treatment from an engineering and science perspective. When considering each cell in our body as a giant molecule, it appears that many functional substances (glycans and proteins) are presented on its surface. Therefore, we have discovered that by artificially gathering functional substances to create multivalent (cluster-type) compounds, we can produce substances with enhanced activity. Currently, we are conducting research and development aimed at creating functional substances and inducing multivalent compounds, leading to new drug discovery.
Manufacturing of organic rubber chemicals, antibacterial agents for fruit trees, and environmental agents.
Main products: organic rubber chemicals, antibacterial agents for fruit trees, environmental agents, pharmaceutical raw materials, and other chemical products.
We have discovered functional molecules that artificially and reversibly open and close the blood-brain barrier.
*Looking for partner companies for joint development* The blood-brain barrier (BBB) has an important function in preventing harmful substances from entering the brain and maintaining a healthy environment within it. However, due to the presence of the BBB, water-soluble drugs administered peripherally cannot be delivered to the brain, and conversely, it has not been possible to restore the function of the BBB once it has opened due to pathological conditions such as neurodegenerative diseases. Recently, Yamaguchi University has established a method to artificially and reversibly open and close the BBB. By identifying the key factors involved in the opening and closing of the BBB and utilizing its physiological functions, it is now possible to reversibly open the BBB under conditions with minimal concerns about side effects, paving the way for drug delivery to the brain, which has been challenging. Additionally, restoring the function of the pathologically opened BBB is expected to improve disease conditions. <Target Diseases> - Closing an opened BBB: cerebral infarction, diabetic retinopathy, Alzheimer's disease, Parkinson's disease, etc. - Opening a closed BBB: brain tumors, neurological diseases, etc. <Benefits for Companies> - The development of new, highly safe therapeutic drugs is now possible through a novel mechanism that allows for the artificial and reversible opening and closing of the BBB.
![[Analysis Case] Evaluation of Ingredients in Tablet-Type Headache Medicine](https://image.mono.ipros.com/public/product/image/2c2/2000254413/IPROS7857973083684944959.jpg?w=280&h=280)
Comparison of ingredients between new products and those after harsh testing; estimation of the structure of unknown components.
We conducted LC/MS analysis to compare how the components in commercially available tablet-type headache medications change before and after harsh testing. The LC/MS total ion chromatogram (TIC) revealed the presence of characteristic components that were not found in the new product after the harsh testing, and the precise mass was identified through the MS spectrum. Furthermore, by performing LC/MS/MS analysis, we were able to estimate the structure based on the information from fragment ions. The combination of LC/MS and LC/MS/MS allows for the structural estimation of unknown components.
